Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae Woo Jung, Woo Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye Ryun Kang, Dong Wan Kim, Chul Woo Kim, Dae Seog Heo

Research output: Contribution to journalArticle

1 Scopus citations


Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLB-CL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods: The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor’s progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria. Results: IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029). Conclusions: Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement.

Original languageEnglish
Pages (from-to)885-893
Number of pages9
JournalKorean Journal of Internal Medicine
Issue number4
StatePublished - 1 Jan 2019



  • Characteristics
  • Diffuse
  • Infusion-related reaction
  • Large B-cell
  • Lymphoma
  • Prognosis
  • Rituximab

Cite this